Skip to main content


Fig. 1 | EJNMMI Research

Fig. 1

From: Comparison of the radiolabeled PSMA-inhibitor 111In-PSMA-617 and the radiolabeled GRP-R antagonist 111In-RM2 in primary prostate cancer samples

Fig. 1

Comparison between 111In-RM2 (a–c) and 111In-PSMA (d–f) on a low-risk sample: radioactive signal (a, d), HES (c, f), and fusion images (b, e). The black line drawing corresponds to the tumoral area. There is good discrimination between tumor tissue and normal tissue on 111In-RM2 (tumor-to-normal ratio, TNR = 1.22) as well as on 111In-PSMA-617 (TNR = 2.09)

Back to article page